Left Menu
Development News Edition

Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient

The company did not discuss its supply strategy for developed nations outside the United States. Remdesivir's price has been a topic of intense debate since U.S. regulators approved its emergency use in some COVID-19 patients in May. Experts have said Gilead would need to avoid appearing to take advantage of a health crisis for profits.

Reuters | Washington DC | Updated: 29-06-2020 23:16 IST | Created: 29-06-2020 22:28 IST
Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient
Representative image Image Credit: ANI

Gilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months. The price tag is slightly below the range of $2,520 to $2,800 suggested last week by U.S. drug pricing research group the Institute for Clinical and Economic Review (ICER) after British researchers said they found that the cheap, widely available steroid dexamethasone significantly reduced mortality among severely ill COVID-19 patients.

Remdesivir is expected to be in high demand as one of the only treatments shown to alter the course of COVID-19. After the intravenously administered medicine helped shorten hospital recovery times in a clinical trial, it won emergency use authorization in the United States and full approval in Japan. For U.S. patients with commercial insurance, Gilead said it will charge $3,120 for a five-day treatment course, or $520 per vial. That is a 33% increase over the $390 per vial Gilead said it will charge governments of developed countries and U.S. patients in government healthcare programs.

In an open letter, Gilead Chief Executive Daniel O'Day said the price is well below the value it provides given that early hospital discharges could save around $12,000 per patient in the United States. Patient advocates like Public Citizen argue that the cost should be lower since remdesivir was developed with financial support from the U.S. government.

Peter Maybarduk, director of Public Citizen's Access to Medicines Program, called the price "an offensive display of hubris and disregard for the public." While the drug modestly reduced hospital stays, it has not been shown to reduce deaths in COVID-19 patients. Gilead also said it agreed to continue to send its supply of remdesivir to the U.S. Department of Health and Human Services (HHS), with the agency and states set to manage allocation to U.S. hospitals until the end of September.

HHS said it secured more than 500,000 remdesivir courses for U.S. hospitals through September, which represents all of Gilead's projected production for July and 90% of its production in August and September, in addition to an allocation for clinical trials, HHS said. Once supplies are less constrained, HHS will stop managing the allocation, Gilead said. The company did not discuss its supply strategy for developed nations outside the United States.

Remdesivir's price has been a topic of intense debate since U.S. regulators approved its emergency use in some COVID-19 patients in May. Experts have said Gilead would need to avoid appearing to take advantage of a health crisis for profits. Gilead shares were about flat in midday trading.

The European Union's healthcare regulator last week recommended conditional approval of the drug when used in the critically ill. The formal go-ahead by the European Commission is expected to follow soon. Gilead has linked up with generic drugmakers based in India and Pakistan, including Cipla Ltd and Hetero Labs Ltd, to make and supply remdesivir in 127 developing countries.

Cipla's version is priced at less than 5,000 Indian rupees ($66.24), while Hetero Lab's version is priced at 5,400 rupees ($71.54). ($1 = 75.4825 Indian rupees)


TRENDING

OPINION / BLOG / INTERVIEW

Why COVID-19 is unstoppable in USA despite it being ranked at the top of GHS Index?

Several worst-hit countries such as Italy, France, Spain, the UK, Canada, and Russia have peaked COVID-19 cases in April. Almost all of them have gradually flattened the curve. However, the USA is setting new daily records of infections tha...

COVID-19 seems cooking biggest ever global scam

The increasing number of corruption cases on COVID-19 funds from throughout the world and involvement of high profile persons indicate that the countries cant ignore corruption in their pandemic response programs. This has generated the nee...

Health Management Information Systems lack holistic, integrated, and pandemic resilient character

Being a part of the United Nations system, the World Health Organization WHO deserves its share of rebuke for its alleged failure issue COVID-19 health emergency alerts on appropriate time. However, the pandemic has also exposed loopholes i...

Pride in the time of coronavirus: a welcome move online?

This year is different in many ways not least as celebrations are also taking place against the dramatic backdrop of a global health crisis and a resurgence in grassroots activism following the death of George Floyd in Minneapolis. ...

Videos

Latest News

Over 5.80 lakh Indians have returned under Vande Bharat mission: MEA

Over 5.80 lakh Indians have returned from abroad after the government launched the Vande Bharat evacuation mission on May 7 in view of the coronavirus pandemic, the Ministry of External Affairs said on Thursday. External Affairs Ministry Sp...

Soccer-Rio shelves plan to allow fans into matches

The mayor of Rio de Janeiro has shelved a plan to allow fans back into professional soccer matches and warned residents of the resort city on Thursday they are courting trouble by continuing to frequent its famous beaches. Sunbathing and sw...

Russian activists planning anti-Putin protest detained, says opposition

Two Russian activists involved in a campaign against what they say are President Vladimir Putins illegal plans to remain in power were detained by authorities on Thursday and five others were questioned and had their homes searched, an anti...

ICMR plans pan-India survey to determine exposure of population to coronavirus

The ICMR on Thursday said a nationwide survey to determine the exposure of the novel coronavirus among the population will be carried out as a follow-up to a similar study conducted in May, the results of which are yet to be released. The I...

Give Feedback